November 14, 2017 EyeGate Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Business Update
(WorldNews Entertainment)

WALTHAM, Mass., Nov. 14, 2017 - EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (`EyeGate` or the `Company`), a clinical-stage, specialty pharmaceutical company with two proprietary platform technologies for treating diseases and disorders of the eye, today announced financial results for the three-month period ended September 30, 2017, and provided an update on recent corporate and operational activities. Third Quarter 2017 and Recent Business Highlights: Completed patient enrollment in the Phase 2b clinical trial of the EGP-437 combination product for the treatment of pain and inflammation in patients having undergone cataract surgery; Strengthened the Company`s management with appointment of...